Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants.
about
Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroadsA comprehensive proteomic view of responses of A549 type II alveolar epithelial cells to human respiratory syncytial virus infectionProgress in understanding and controlling respiratory syncytial virus: still crazy after all these yearsEliminating antibody polyreactivity through addition of N-linked glycosylation.Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse geneticsGeneration and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.Vaccination against RSV: is maternal vaccination a good alternative to other approaches?Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection.Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein.Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development.Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody.Vaccines Against Respiratory Syncytial Virus: The Time Has Come.Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.Neonatal Immunity, Respiratory Virus Infections, and the Development of Asthma.
P2860
Q33916408-C9E7DFC1-CF9A-4062-8900-B17DA839984DQ34634867-5881F24C-4E5C-490A-80CA-2EDF351A06D0Q35566601-403F0C0C-03B6-410D-88B8-210128D7E8E8Q35684786-A0ACB235-FE17-4CFC-A84E-48CDC2E193CCQ36276526-802CE332-FBEC-4B9D-B23F-9C32C6ED1C2DQ36438987-36F45B0D-F44B-4F48-B95B-DEFAA9E7F096Q37514757-ED0D0706-AA99-43AC-B1F8-2469CDEE7A52Q38750689-69D6C273-294A-44A6-B365-0DDF3826B76BQ40046506-A7174747-6E5D-4693-8214-445C62467C31Q40092356-B333CA6E-EDBD-40FB-9E5E-0D24598B011FQ40812866-04D5F877-D1FF-404F-8D9D-C0130A9AB34FQ41857868-739B290F-5A23-428A-AE0B-0DB9E35FDA9DQ45332913-2DAB1985-DCAE-489F-97E9-B0A0C038CBDEQ47553316-42A0D31F-3BF5-4358-9E29-2DA80D29CA22Q55293109-C2F01CC8-4F8E-4674-A4FE-FBA09777CFA2
P2860
Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Review of palivizumab in the p ...... us (RSV) in high-risk infants.
@en
Review of palivizumab in the prophylaxis of respiratory syncytial virus
@nl
type
label
Review of palivizumab in the p ...... us (RSV) in high-risk infants.
@en
Review of palivizumab in the prophylaxis of respiratory syncytial virus
@nl
prefLabel
Review of palivizumab in the p ...... us (RSV) in high-risk infants.
@en
Review of palivizumab in the prophylaxis of respiratory syncytial virus
@nl
P2860
P356
P1476
Review of palivizumab in the p ...... us (RSV) in high-risk infants.
@en
P2093
Octavio Ramilo
P2860
P304
P356
10.2147/BTT.S3104
P577
2008-09-01T00:00:00Z